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Abstract
Background: The 2009 H1N1 pandemic highlighted the need to routinely monitor severe influenza, which lead to the
establishment of sentinel hospital-based surveillance of severe acute respiratory infections (SARI) in several countries in
Europe. The objective of this study is to describe characteristics of SARI patients and to explore risk factors for a severe
outcome in influenza-positive SARI patients.
Methods: Data on hospitalised patients meeting a syndromic SARI case definition between 2009 and 2012 from nine
countries in Eastern Europe (Albania, Armenia, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Romania, Russian Federation
and Ukraine) were included in this study. An exploratory analysis was performed to assess the association between risk
factors and a severe (ICU, fatal) outcome in influenza-positive SARI patients using a multivariate logistic regression
analysis.
Results: Nine countries reported a total of 13,275 SARI patients. The majority of SARI patients reported in these
countries were young children. A total of 12,673 SARI cases (95%) were tested for influenza virus and 3377 (27%) were
laboratory confirmed. The majority of tested SARI cases were from Georgia, the Russian Federation and Ukraine and the
least were from Kyrgyzstan. The proportion positive varied by country, season and age group, with a tendency to a
higher proportion positive in the 15+ yrs age group in six of the countries. ICU admission and fatal outcome were
most often recorded for influenza-positive SARI cases aged >15 yrs. An exploratory analysis using pooled data from
influenza-positive SARI cases in three countries showed that age > 15 yrs, having lung, heart, kidney or liver disease,
and being pregnant were independently associated with a fatal outcome.
Conclusions: Countries in Eastern Europe have been able to collect data through routine monitoring of severe
influenza and results on risk factors for a severe outcome in influenza-positive SARI cases have identified several risk
groups. This is especially relevant in the light of an overall low vaccination uptake and antiviral use in Eastern Europe,
since information on risk factors will help in targeting and prioritising vulnerable populations.
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Background
Surveillance of influenza is important for determining
the timing and spread of influenza, for tracking changes
in circulating influenza viruses to inform seasonal influ-
enza vaccine composition, and as an alert mechanism
for potential pandemic viruses [1]. One of the gaps in in-
fluenza surveillance highlighted during the 2009 pan-
demic was the lack of systems that routinely monitor
severe influenza. There was also limited timely informa-
tion on risk factors associated with a severe outcome in
hospitalised patients with influenza.
A recent evaluation of 2009 pandemic and seasonal in-
fluenza epidemics due to A(H1N1) and A(H3N2) viruses
has shown that the morbidity by age group was similar,
but that young age was an important risk factor for
death only during the 2009 H1N1 pandemic [2]. In
addition, obesity and pregnancy were identified as risk
factors for a severe outcome of influenza A(H1N1)
pdm09 infection compared to seasonal influenza [3] and
having an underlying disease was a risk factor for a se-
vere outcome due to pandemic and seasonal influenza
viruses [4-7]. However, most of the studies on risk fac-
tors for a severe outcome of influenza that are available
are from developed and/or high income countries; there
is limited information on risk groups in low- and
middle-income countries [8,9] and the role of influenza
in SARI patients for countries in Central and Eastern
Europe, where the antiviral treatment and vaccination
uptake [10,11] are low.
Sentinel surveillance for hospitalised patients meeting a
syndromic Severe Acute Respiratory Infection (SARI) case
definition has recently been established in countries in the
World Health Organization (WHO) European Region. By
the end of the first post-pandemic influenza season
(2010–2011), a total of 11 countries had established senti-
nel SARI surveillance using standard methods based on
guidance published by the WHO Regional Office for
Europe [12]. This paper describes the characteristics of
SARI patients and investigates risk factors for a severe
outcome (ICU/fatal) in influenza-positive SARI patients in
countries in Central and Eastern Europe.
Methods
Data collection
Countries that performed influenza surveillance in the
WHO European Region and collected case-based data
on SARI patients as part of their national influenza sur-
veillance between 2009 and 2012 were invited to partici-
pate in the study. For inclusion, as a minimum, data on
age, gender, clinical symptoms, presence and specifica-
tion of underlying conditions, and influenza (sub)type la-
boratory test results were required for each case. Testing
of all hospitalised patients that met the SARI case defin-
ition at the sentinel sites was recommended in the
WHO Euro guidelines [12]. Sampling and testing proce-
dures were the same during and after the pandemic.
Countries that met the inclusion criteria on the mini-
mum data requirements were asked to provide the fol-
lowing information on SARI patients: geographical
region/district of the hospital, hospital, gender (male, fe-
male), date of birth/age, case definition, date onset influ-
enza, sampling date, sample type (nasal swab, throat
swab, combined nasal/throat swab, aspirate, bronchoal-
veolar lavage (BAL), tissue from biopsy or autopsy, other,
unknown/not specified), clinical symptoms, existing
underlying conditions (yes/no), asthma (yes/no), diabetes
(yes/no), cancer (yes/no), immune-compromised (yes/
no), heart (yes/no), kidney (yes/no), lung (yes/no), liver
(yes/no), neurological (yes/no), obesity (no, BMI 30–40,
BMI > 40, clinically obese), pregnancy (yes/no), preg-
nancy trimester (1st trimester, 2nd trimester, 3rd trimes-
ter), vaccination status (yes/no), antiviral prophylaxis
(yes/no), antiviral treatment (yes/no), antiviral resistance
(yes/no), respiratory support (no, oxygen, ventilation,
ECMO), pneumonia diagnosis (no, yes (clinical/abnor-
mal chest X-ray/raised CRP level), Tuberculosis (TB) (no
history of TB, history of TB, positive test during hos-
pital), influenza test (not performed, polymerase chain
reaction (PCR), culture, immunofluorescent assay (IFA),
other -not specified- test), test result (negative/positive),
influenza type (A/B), influenza A subtype (A(H1N1)
pdm09, A(H3N2)), ICU admission, outcome (discharged
alive/death), and cause of death (not influenza, influenza
as a primary cause, influenza as a secondary cause).
A descriptive analysis was performed to investigate the
SARI patient characteristics by influenza status and
country. The season was defined from 1 August to 31
July the following year. Pregnancy and obesity were in-
cluded when determining the total number of multiple
underlying conditions. Except for pregnancy, the per-
centage of patients with a specific condition was calcu-
lated by dividing the total number of patients with the
condition by the total number of patients with available
data for that variable. The percentage of pregnant
women was defined by dividing the number of pregnant
women by the number of women of childbearing age
(15–49 yrs).
Statistical analysis
We assessed the association between possible risk fac-
tors (i.e. age (categorical), gender, underlying conditions,
influenza subtype) and different levels of severity for
influenza-positive SARI patients. Only cases with avail-
able risk data were included in the analysis. Four patient
outcomes were defined: 1) SARI patients that were not
admitted to ICU and discharged alive, 2) SARI patients
admitted to ICU and discharged alive, 3) SARI patients
that died, and 4) SARI patients with any severe outcome
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(patients that were admitted to ICU or died). The three
more severe levels were compared to the least severe
outcome: SARI patients who were not admitted to ICU
and discharged alive. The influenza subtype A(H1N1)
pdm09 (vs. non-influenza subtype A(H1N1)pdm09) was
also included as possible risk factor for a severe out-
come. Because data on vaccination status and antiviral
treatment were incomplete -or numbers were very low-
we did not include these variables in the data analysis.
Logistic regression analysis was performed to identify
factors associated with a severe outcome. All variables
associated with a severe outcome at a significance level
of p <0.15 were included in a multivariate logistic regres-
sion analysis (Enter method) to identify factors inde-
pendently associated with ICU admission or death. A
factor was defined significant when p < 0.05 in the multi-
variate analysis. For categorical variables with >2 levels,
the Chi-squared test was used, while for categorical vari-
ables with 2 categories (2×2 table) the Continuity Cor-
rection was used. Correlation between variables was
checked and if the Pearson correlation was >0.5, we in-
cluded only one of the variables in the analysis. Finally, a
pooled data analysis was performed for countries that
had collected data on both ICU admission and deaths.
Variables that were significant in the univariate logis-
tic regression analysis were included in the multivari-
ate analysis. To control for differences between
countries, the country (Romania = reference category,
Albania = dummy1, Georgia = dummy2) was included
as a factor in the model. SPSS 20 was used for the
analyses.
Ethical considerations
Verbal consent was obtained from all patients before spe-
cimen collection as per country’s routine public health
practice. WHO Regional Office for Europe considered
that anonymised data collected through sentinel hospital
surveillance for influenza to be part of routine public
health surveillance; therefore, formal ethical review was
not required.
Results
Eleven countries performed SARI surveillance and
were contacted to participate in the study. Nine coun-
tries (Albania, Armenia, Belarus, Georgia, Kazakhstan,
Kyrgyzstan, Romania, Russian Federation and Ukraine)
fulfilled the inclusion criteria and were included in the
study. For each country a description of the popula-
tion, age distribution and other health-related topics is
available in Table 1 [13]. The population of the coun-
tries participating in this project varies from 3.2 mil-
lion in Armenia and Albania to 142.6 million in the
Russian Federation. The age distribution is similar for
the countries with the exception of Kazakhstan and
Kyrgyzstan where children (0–14) represent a substan-
tial (24-30%) proportion of the population. The num-
ber of hospitals available per 100,000 of the population
range from 1.4 in Albania to 7.0 in Belarus. Outpatient
contacts per person -the total number of primary
health care or ambulatory care contacts divided by the
population- vary by country. They are relatively low at
in Albania (2.0) and Georgia (2.1), and high in Belarus
(13.2) and Ukraine (10.7). The system characteristics
including SARI case definitions are presented in Table 2
and additional information on the SARI surveillance
descriptions can be found at the WHO Regional Office
for Europe website [14].
From 2009 to 2012, a total of 13,275 SARI patients
were reported. Overall, the majority of SARI patients re-
ported in these countries were young children and the
large majority of SARI patients (95%) were tested for in-
fluenza virus. This small group of SARI patients that
were not tested were generally children with no under-
lying medical conditions (Additional file 1: Table A). Dif-
ferent types of hospitals were included in the SARI
Table 1 Country population and health care data
Albania Armenia Belarus Georgia Kazakhstan Kyrgyzstan Romania Russian
Federation
Ukraine
Mid-year population (in million) 3.2 3.2 9.5 4.5 16.4 5.5 21.4 142.6 45.6
% population aged 0–14 years - 18.5 17.0 17.0 24.4 30.2 15.1 15.2 14.2
% population aged 65+ years - 10.3 13.9 13.8 6.7 4.5 14.9 12.8 15.5
Live births/year (x1000) (2009) 34 44.4 109.2 63.3 357.5 135.5 222.4 1761.7 512.5
Crude death rate per 1000 pop (2009) - 8.5 13.97 10.57 8.97 6.67 11.98 14.17 15.41
Hospitals per 100.000 population 1.4 4.0 7.0 6.2 6.1 2.7 2.6 na 6.1
Hospital beds per 100.000 population 267 381 1126 286 725 476 634 na 919
Outpatient contacts/person per year 2.0 3.5 13.2 2.1 6.9 3.6 4.7 9.5 10.7
Source: European Health for All database (HFA-DB) (http://data.euro.who.int/hfadb/). The mean for the period 2009–2012 was calculated, except for % population
where data from 2009/2010 are presented.
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Table 2 SARI data collection in nine countries in the WHO European Region, 2009-2012
Albania Armenia Belarus Georgia Kazakhstan Kyrgyzstan Romania Russian
Federation
Ukraine
Number of
sentinel hospitals
15 6/7 11 6 17 4 12-26 19 9-10
Period data
collection
Nov 2009-
Mar 2011
Dec 2010-
Mar 2012
Sep 2010-
Dec 2012
Jan 2009-Mar
2012
Sep 2011-Dec
2012
Nov 2010-Jun
2011
Oct 2009-May 2012 Sep 2010-Dec
2012
Sep 2009-Dec 2012
Case definition
-all ages
Standarda Newcd Standardae Newcd
Case definition <5 WHOb Pneumb Pneumb Pneumb Pneumb Pneumb
Case definition ≥ 5 Standarda Standarda Standarda Standarda Standarda Standarda
No. SARI cases 102 335 1025 2138 857 369 1003 2779 4667
No. children
aged 0–14 (%)
24 (23.5%) 287 (85.7%) 412 (40.1%) 1137 (53.5%) 538 (62.8%) 267 (72.4%) 491 (49.0%) 1718 (61.8%) 2339 (50.1%)
No. SARI tested
influenza (%)
102 (100%) 188 (56.1%) 1025 (100%) 2138 (100%) 834 (97.3%) 43 (11.6%) 914 (91.1%) 2779 (100%) 4650 (99.6%)
Type of hospital
included
ID, PED,
PULM, ICU
GEN, ID, PED,
EM, GYN
GEN, ID,
PED, EM
GEN, ID, PED,
EM, ICU
ID, PED, EM GEN, ID, PED ID, PED, PULM, EM GEN, ID, PED, EM GEN, ID, PED
Number of beds
per hospital
76-436 50-500 1000 63-250 100-395 180-400 92-1556 na 110-645
Catchment area
and/or site
selection
1 hospital in
each of 12
counties + 3
hospitals in
Tirana.
1 hospital
in 2
regions
and 5
hospitals in
Yerevan.
The 11
hospitals are
located in
large cities
of the
country’s 6
regions.
SARI admission
rates and
collaboration NCDC
used to identify
sitese Most regions
of the country
were covered.
The
hospitals
located in 7
regions of
the country.
Sites are located
in 2 cities
(Bishkek and
Osh). The sites
serve about 1.5
million of the
population.
Sites are regional
clinical hospitals,
well equipped for
care to SARI cases,
and cover 19-30%
of population.
Sites (1–2) are
located in 9 cities
in 6 Federal
districts. The 9
cities cover a
population of
10.5 million.
Sites (10) are located in 4
cities in different
geographical parts of
the country.
Monitoring
data quality
Sentinel site
visit
Sentinel
site visit.
Monthly
during
season
Weekly
basis
Monthly during
seasonf
All year
round
Two times a
year at the
national level
Weekly at the national
level by the SARI
coordinator.
Weekly basis Weekly at the national
level by the SARI
coordinator.
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Table 2 SARI data collection in nine countries in the WHO European Region, 2009-2012 (Continued)
Vaccination
recommendations
(rec)g /risk groups
and coverage
Children< 5,
Elderly >65,
persons with
underlying
diseases, HCW
WHO rec. WHO rec.
Pregnant
women
obligatory
since 2011
WHO rec. Pregnant
women, persons
with underlying
diseasesh, > 65 yrs,
children <2.
Coverage in risk
groups is 90%
WHO rec.
Coverage in
risk groups
is 98-100%
Vaccination
coverage in risk
groups is about
3% (HCW,
children and
pilgrims)
WHO rec. Persons 6
months-64 years old
with chronic underlying
conditions, pregnant
women, HCW, staff
working with
institutionalised
persons, residents
of the social care
institutions, persons
≥65 years old. Coverage
is: Tot: 5.2-14.6%; 65+:
19.1%-49.4% HCW:
51%-97.8%
WHO rec. >30
mln of population
each year
Age >60, underlying disease
(chronic cardio-vascular,
lung, kidney, liver, HIV,
diabetes, primary
immunodeficiency),
pregnancy, HCW
Method influenza
detectioni
PCR PCR,
culture
PCR PCR PCR, other,
culture
PCR, other Real-time PCR for type
and subtype detection
PCR PCR, other
Abbreviations: ICU Intensive care unit, Na not available, PCR polymerase chain reaction, SARI severe acute respiratory infection, GEN general/multi-profile/national referral, ID infectious disease, PED paediatrics, EM
emergency, PULM Pulmonology, GYN obstetrics and gynecology/maternal department, HCW Health care workers.
aThe standard SARI case definition is defined as a patient with onset of the following symptoms ≤ 7 days prior to hospitalisation:
Fever >38°C AND cough OR sore throat AND shortness of breath or difficulty in breathing.
bThe WHO case definition is defined for pneumonia and severe pneumonia in children below the age of 5, and is as follows:
Pneumonia: cough OR difficulty breathing AND breathing faster than 40 breaths/minute (12–59 month) or breathing faster than 50 breaths/minute (2–11 month);
Severe pneumonia: cough OR difficulty breathing AND any of the following severe signs: unable to drink or breastfeed, OR vomits everything, OR convulsions, OR lethargic or unconscious, OR chest indrawing or
stridor in a calm child.
cNew WHO case definition – all ages.
An acute respiratory illness with onset in the 7 days prior to hospital admission, that results in hospitalization over night and includes:
History of fever or measured fever of ≥ 38°C, AND cough, AND shortness of breath or difficulty breathing.
dThe new WHO case definition cdc was used in the 2011–2012 influenza season, for the seasons before 2011–2012 the WHO case definitionab was used.
eSites were selected according to their SARI admission rates and collaboration with NCDC, most regions of the country were covered. In the first year 2008–2009 the surveillance was nationwide, in 2009–2010 a
transition to a sentinel system was made, and was capable to provide representative data (personal communication).
fThe sentinel epidemiologist monitors the data collection at a regular basis. The NCDC specialist visits the sentinel site and checks sentinel data on quarterly basis and monthly during the active influenza season
(Personal communication Giorgi Chakhunashvili).
gRecommended risk groups for seasonal influenza vaccination are: pregnant women (highest priority) and in no particular order of priority: children aged 6 to 59 months, the elderly, individuals with specific chronic
medical conditions, and health-care workers [8].
hCardiovascular disorder, respiratory disorder, kidney disorders, hepatitis, HIV, diabetes, immunocompromised persons, oncological patients.
iIn case culture is used, this is performed in 1% of all tests.
Note: country-specific information in this table (type of hospital included, number of beds per hospital, catchment area and/or site selection, monitoring data quality, vaccination recommendations) are kindly provided
by the co-authors of this paper (personal communication).
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surveillance (Table 2), of which infectious disease hospitals,
general/multi-profile/national referral hospitals, paediatric
hospitals and emergency hospitals were more common. In
Albania and Georgia ICU facilities were included in the
surveillance and in Armenia an obstetrics and gynaeco-
logy/maternity department was included. The number of
beds per hospital and other surveillance-related topics such
as the recommended risk groups for vaccination [8] can be
found in Table 2. An assessment on the proportion of
SARI cases admitted and cases included in the surveillance
were only available for Romania and amounted 25% of
SARI patients (Personal communication: Odette Nicolae).
The results of SARI surveillance varied by country
and the number of SARI samples tested, samples tested
positive for influenza, the virus detections and fatal
cases are summarised by country, season and age group
in Table 3. Georgia reported data for four influenza sea-
sons (from start of 2009 till 2012), while Kazakhstan
(2011–2012) and Kyrgyzstan (2010–2011) collected
data for one influenza season. Overall, the highest pro-
portion of influenza-positive cases were reported in
Albania (100% in 2009–2010) and in Georgia (75.2% in
2010–2011). The proportion positive varied by country,
season and age group, with a tendency to a higher pro-
portion positive in the 15+ yrs age group in Albania,
Armenia, Kazakhstan, Romania, the Russian Federation
and Ukraine. The highest proportion of pregnant women
was observed in influenza-positive SARI patients in
Armenia (73%) and the Russian Federation (61%), and
lowest in Kyrgyzstan (0%), Albania (12.5%) and Ukraine
(15%). See Additional file 1: Table A.
The (sub)typed influenza viruses reported differed by
season, e.g. in Georgia in the 2010–2011 season influenza
B (48.2%) co-circulated with influenza A(H1N1)pdm09
(50.7%), and a substantial proportion of fatal cases in the
older adults were infected with influenza B (Figure 1). In
Ukraine the influenza A(H1N1)pdm09 virus was domin-
ant (91%) in the 2009–2010 influenza season. Influenza A
(H1N1)pdm09 (40.8%) and B (55.3%) were co-dominant
in the 2010–2011 season and influenza A(H3N2) was
dominant (91%) during the 2011–2012 influenza season.
A similar pattern could be observed for Romania (Table 3).
In terms of fatal cases these were most often recorded in
patients aged >15 yrs of age.
Data on the ICU admission status of hospitalised SARI
patients were collected by six countries (Armenia, Albania,
Belarus, Georgia, Kazakhstan and Romania). ICU admis-
sion in influenza-positive SARI patients ranged from 6.3%
in Kazakhstan to 56.5% in Armenia. Information on deaths
was available for Albania, Armenia, Georgia, Romania and
Ukraine; the % of influenza-positive SARI patients that
died ranged from 0.8% in Ukraine to 18.8% in Albania. See
for detailed characteristics by country the Additional file 1:
Table A.
In Figure 2 the influenza-positive SARI cases are pre-
sented by severity; cases not admitted to ICU, non-fatal
cases admitted to ICU, and cases with a fatal outcome.
Data on both ICU and fatal cases were available for
Albania, Armenia, Georgia and Romania and are pre-
sented. Overall, most fatal SARI cases occurred in the
age groups 25–49 yrs and 50–64 yrs with only one fatal-
ity reported in the 0–2 year old age group, but this was
identified as being “not due to influenza”. In Georgia, a
substantial number of fatal cases were reported in the
age group >65 yrs. We also evaluated the detected influ-
enza virus (sub)type and severity for Georgia and
Romania, as they had sufficient data for this (Figure 1).
Most SARI patients were influenza A(H1N1)pdm09
positive. Data from Georgia presenting influenza B posi-
tive patients indicated that practically all adults were ad-
mitted to ICU or had a fatal outcome. A relatively low
number of SARI patients tested positive for influenza A
(H3N2) in the period 2009–2012.
Influenza vaccination rates in all countries were very
low. Seven out of nine countries had data on the vaccin-
ation status of the SARI cases. For the influenza-
negative SARI patients the proportion vaccinated for in-
fluenza ranged from 0–3.2%, and for influenza-positive
cases 0–4.1%. The use of antiviral medication to treat
influenza-positive SARI patients was low and ranged
from 0.5% in Kazakhstan to about 35% in Armenia
(Additional file 1: Table A). Generally, the neuraminid-
ase inhibitor oseltamivir was used as antiviral treatment.
To explore a possible association between known risk
factors and a severe outcome, we presented the risk fac-
tors for influenza-positive SARI patients by outcome: pa-
tients that were not admitted to ICU, patients admitted
to ICU, patients that died and patients that were admit-
ted to ICU or who died (Additional file 1: Table B). We
observed that a substantial proportion of the patients
admitted to the ICU or that died had underlying medical
conditions. The univariate logistic regression analysis on
the country level revealed that age >15 yrs, being in-
fected with influenza A(H1N1)pdm09, and having
underlying conditions (in particular being immune-
compromised, or pregnant or having lung or heart dis-
ease) were significantly associated with a fatal outcome
(Additional file 1: Table C).
In the multivariate analysis using logistic regression we
investigated the association of previously identified risk
factors in influenza-positive SARI patients with a severe
outcome (i.e. being fatal, admitted to ICU or fatal/ICU)
for Albania, Georgia and Romania (Figure 3). We ex-
cluded data from Armenia from the multivariate analysis
because of insufficient data. The data were not represen-
tative for the general population, as evidenced by the ex-
tremely high proportion of pregnant women in the data.
Below we present the results for the logistic regression
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Table 3 Description of SARI patients testing positive for influenza by country, season and age group (<15, 15+)
Country and
season
Samples
tested
Samples
positive (%)
Influenza
A
Influenza
A(H1N1) pdm09
Influenza
A(H3N2)
Influenza A
(not sub- typed)
Influenza
B
Fatal
cases (%)
Albania 2009-2010 58 58 (100%) 58 55 3 0 0 13/58 (22.4%)
<15 years 12 12 (100%) 12 11 1 - - 0/12 (0%)
15+ years 46 46 (100%) 46 44 2 - - 13/46 (28.3%)
2010-2011 44 10 (22.7%) 10 8 2 0 0 0/10 (0%)
<15 years 12 2 (16.7%) 2 2 0 - - -
15+ years 32 8 (25%) 8 6 2 - - -
Armenia 2010-2011 140 22 (15.7%) 17a 9 0 - 5 1/22 (4.5%)
<15 years 109 8 (7.3%) 5a 0 0 - 3 1/8 (12.5%)
15+ years 31 14 (45.2%) 12a 9 0 - 2 0/22 (0%)
2011-2012 48 1 (2.1%) 1 0 1 - 0 0/1
<15 years 39 0 (0%) 0 - 0 - 0 -
15+ years 9 1 (11.1%) 1 - 1 - 0 0/1
Belarus 2010-2011 380 35 (9.2%) 24 24 - - 11 Na
<15 years 105 10 (9.5%) 7 7 - - 3
15+ years 275 25 (9.1%) 17 17 - - 8
2011-2012 635 16 (2.5%) 16 1 15 - 0 Na
<15 years 306 8 (2.6%) 8 1 7 - -
15+ years 329 8 (2.3%) 8 0 8 - -
Georgia 2008-2009 196 46 (23.5%) 42 39 3 0 4 0/46 (0%)
<15 years 163 33 (20.2%) 29 26 3 - 4 0/33 (0%)
15+ years 33 13 (39.4%) 13 13 0 - 0 0/13 (0%)
2009-2010 1526 531 (34.8%) 499 484 11 4 32 31/531 (5.8%)
<15 years 1051 327 (31%) 296 281 11 4 31 7/327 (2.1%)
15+ years 475 204 (2.3%) 203 203 0 0 1 24/204 (11.8%)
2010-2011 375 282 (75.2%) 146 143 1 2 136 53/282 (18.8%)
<15 years 196 150 (76.5%) 63 62 1 0 87 3/150 (2.0%)
15+ years 179 132 (73.7%) 83 81 0 2 49 50/132 (37.9%)
2011-2012 21 10 (47.6%) 10 5 5 0 0 7/10 (70%)
<15 years 6 4 (66.7%) 4 4 0 - - 1/4 (25%)
15+ years 15 6 (40%) 6 1 5 - - 6/6 (100%)
Kazakhstan 2011-2012 791 186a (23.5%) 171a 54 100 2 10 0/38*
<15 years 509 95a (18.7%) 90a 23 59 - 2 0/21*
15+ years 282 91a (32.3%) 81a 31 41 2 8 0/17*
Kyrgyzstan 2010-2011 43 19 (44.2%) 19 10 9 - - Na
<15 years 13 13 (100%) 13 5 8
15+ years 30 6 (20%) 6 5 1
Romania 2009-2010 211 66 (31.3%) 66 66 0 - 0 11/66 (16.7%)
<15 years 75 13 (17.3%) 13 13 0 - - 2/13 (15.4%)
15+ years 136 53 (39%) 53 53 0 - - 9/53 (17%)
2010-2011 422 165 (39.1%) 84 83 1 - 81 21/165 (12.7%)
<15 years 203 69 (34%) 18 18 0 - 51 0/69 (0%)
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analyses by country (Albania, Georgia and Romania)
followed by the pooled data analysis results.
The individual country results indicate that for Albania
influenza-positive SARI patients with lung disease
were at increased risk for a fatal outcome (OR = 5.33,
CI95% = 1.10-25.76), and fatal outcome/ICU admission
(OR = 5.42, CI 95% = 1.29-22.69) (Additional file 1:
Table 1D).
In Georgia the following variables were independent risk
factors for a fatal outcome in influenza-positive SARI pa-
tients: age > 15 yrs (OR = 10.73, CI 95% = 3.80-30.28), lung
disease (OR = 43.65, CI 95% = 16.46-115.7), heart disease
(OR = 40.62; CI 95% = 8.34-198.0) and being pregnant
(OR = 18.39, CI 95% = 3.92-86.38). For ICU admission
lung disease (OR = 5.94, CI 95% = 3.35-10.58) and heart
disease (OR = 10.47; CI 95% = 3.45-31.83), as well as being
pregnant (OR = 6.02, CI 95% = 2.22-16.33) were independ-
ent risk factors for ICU admission in influenza-positive
SARI patients. Age > 15 yrs (OR = 9.75; CI 95% = 4.61-
20.61), having lung disease (OR = 14.90, CI 95% = 8.14-
27.27), kidney disease (OR = 8.78, CI 95% = 1.50-51.29)
and being pregnant (OR = 3.27, CI 95% = 1.13-9.49) were
independent risk factors for influenza-positive SARI pa-
tients admitted to ICU or with a fatal outcome (Additional
file 1: Table 4D).
In Romania the following variables were independent
risk factors for a fatal outcome in influenza-positive
SARI patients: being immune-compromised (OR = 3.87,
CI 95% = 1.19-12.60) and being infected with influenza
A(H1N1)pdm09 virus (OR = 7.48, CI 95% = 2.39-23.36).
In Romania, the influenza subtype A(H1N1)pdm09 was
also an independent risk factor (OR = 2.40, CI 95% =
1.39-4.12) for patients with any severe outcome (admit-
ted to ICU or with a fatal) (Additional file 1: Table 7D).
For the pooled data analysis the following variables
were independent risk factors for a fatal outcome in
influenza-positive SARI patients when controlling for
the effect of country: age > 15 (OR = 5.44, CI 95% =
2.77-10.71), lung disease (OR = 14.89, CI95% = 8.62-
25.71), heart disease (OR = 4.01, CI95% = 2.21-7.29),
liver disease (OR = 3.59, CI95% = 1.11-11.42), kidney
disease (OR = 3.88, CI95% = 1.06-14.28) and pregnancy
(OR = 7.08, CI95% = 3.01-16.68), see Figure 3. Although
obesity was a significant risk factor for severe outcome in
some countries in the univariate logistic regression ana-
lysis, we were not able to include this in the pooled
analysis due to incomplete data. No results are presented
for ICU patients and fatal/ICU patients, as the Hosmer
and Lemeshow test for these outcomes were significant
(p = 0.000) and indicated a bad fit with the model.
Table 3 Description of SARI patients testing positive for influenza by country, season and age group (<15, 15+)
(Continued)
15+ years 219 96 (43.8%) 66 65 1 - 30 21/96 (21.9%)
2011-2012 281 69 (24.6%) 68 0 68 - 1 1/69 (1.4%)
<15 years 173 31 (17.9%) 31 0 31 - 0 1/31 (3.2%)
15+ years 108 38 (35.2%) 37 0 37 - 1 0/38 (0%)
Rus. Fed. 2010-2011 1293 274 (21.2%) 203a 178 22 - 71 Na
<15 years 834 103 (12.4%) 73a 62 10 - 30
15+ years 459 171 (37.3%) 130a 116 12 - 41
2011-2012 1486 153a (10.3%) 128 8 120 - 23 Na
<15 years 884 49 (5.5%) 42 2 40 - 7
15+ years 602 104a (17.3%) 86 6 80 - 16
Ukraine 2009-2010 2149 731 (34%) 672 666 0 6 59 10/730 (1.4%)
<15 years 954 248 (26.0%) 231 229 0 2 17 0/247 (0%)
15+ years 1195 483 (40.4%) 441 437 - 4 42 10/483 (2.1%)
2010-2011 2046 490 (23.9%) 219a 200 5 13 271 0/489 (0%)
<15 years 1134 208 (18.3%) 105 101 1 3 103 0/208
15+ years 912 282 (30.9%) 114a 99 4 10 168 0/281
2011-2012 413 188a (45.5%) 179a 0 171 1 6 Na
<15 years 251 107a (42.6%) 102a 0 94 0 2
15+ years 162 81 (50%) 77 0 77 0 4
Na: not available; *Incomplete data; aThe influenza (sub)type information were not available for all influenza-positive SARI patients.
Note: for the countries Albania, Belarus, Georgia and Ukraine the total number of samples tested and/or tested positive are slightly lower compared to the data
presented in the Supplement, this is due to the selection and availability of the influenza type and subtype data, and season/age group information.
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Discussion
Severe influenza surveillance has been established in
nine countries in Eastern Europe and an exploratory
analysis on risk factors for a severe outcome has been
performed for data from Armenia, Georgia and
Romania. We observed that most SARI patients admit-
ted to the hospitals were young children and that
influenza-positive SARI patients were generally more
often admitted to ICU and resulted more often in death
than the influenza-negative SARI patients. Influenza A
(H1N1)pdm09 was generally detected in the 2009–2010
season, whereas influenza B and influenza A(H1N1)
pdm09 were most frequently observed in the 2010–2011
season with influenza B being most prominent in chil-
dren. Influenza A(H3N2) was commonly detected in the
2011–2012 season. Overall, our results indicated that
ICU admission rates for influenza-positive SARI cases
ranged from 6-56%, and fatal cases from 0.8-18.8%.
These findings differed by country, season and age
group. The proportion of ICU admissions and fatal
cases is similar to what has been reported in SARI
cases in nine EU countries by Snacken et al. [15]
where 37% of hospitalised cases were admitted to
ICU, and 15.6% died, and a study from Bagdure et al.
[16] where 26% of hospitalised children infected with
influenza A(H1N1)pdm09 were admitted to the ICU
and 3% died.
Pooled data analysis identified risk factors (>15 yrs of
age, having lung, heart, kidney or liver disease or being
pregnant) for a fatal outcome in influenza-positive SARI
patients. Risk factors for severe outcome for influenza-
positive SARI patients did differ slightly between countries,
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Figure 1 SARI patients presented by age group and influenza (sub)type in two countries, 2009–2012.
Figure 2 SARI patients positive for influenza presented by age group in four countries, 2009–2012.
Meerhoff et al. BMC Infectious Diseases  (2015) 15:1 Page 9 of 12
but overall corresponded to risk factors for a severe out-
come that have been reported in the literature worldwide
[7,17] and were similar to findings in Spain [18]. For
Western Europe limited data are available on hospitalised
severe cases [6,15]. With most of the studies in the litera-
ture focusing on risk factors for a severe outcome in cases
with influenza A(H1N1)pdm09 during the pandemic, our
study evaluated both pandemic and seasonal viruses from
2009–2012. Therefore we need to be careful in interpreting
the results. While literature has shown that the main risk
groups such as having underlying disease are similar for in-
fluenza A(H1N1)pdm09 and seasonal influenza, obesity
was identified as new risk factor for a severe outcome [7].
Many studies, however, have a lack of power and more evi-
dence is needed to improve the level of evidence to identify
risk factors for a severe outcome for pandemic and sea-
sonal influenza [19].
The risk factors for a severe outcome (being > 15 yrs
of age and having underlying disease) were similar for
the three countries but there were also some country
differences. Data from Romania indicated that being
immune-compromised and being infected with the influ-
enza A(H1N1)pdm09 virus were risk factors for a fatal
outcome, but this effect was not observed in the pooled
data analysis. Data for Georgia showed that many pa-
tients in ICU and/or fatal cases were influenza B positive
and this is different from Romania. These findings may
represent country differences, but could also be due to
differences in surveillance systems, local practices or dif-
ferences in circulating viruses. Unfortunately, we were
not able to further investigate the role of the different
virus (sub)types on the outcome due to limited data, in-
cluding differences in the seasonal and pandemic influ-
enza epidemiology.
One of the strengths in this study is the use of a stand-
ard case definition and collecting information on both
influenza-negative and positive SARI cases. Admission
criteria for the hospital and treatment are generally
based on the judgement of the clinician and hospital ad-
missions may not always be related to severity. There-
fore using a case definition is important. Although a
common approach was used, we observed country dif-
ferences in the proportion of children, pregnant women
and elderly being admitted to the hospital. These differ-
ences may be partly explained by a different population
structure, probability of seeking care [20], but also by
the inclusion of different hospital types and wards in the
surveillance system - e.g. the high proportion of pregnant
women in Armenia may be due to the inclusion of the ob-
stetrics/maternity department. Furthermore, young chil-
dren with a respiratory infection may be more likely to be
admitted to the hospital than adults and this may indicate
that different case management policies and criteria are
used for hospital admission.
The proportion of SARI patients testing positive varied
between countries and should be interpreted with cau-
tion. For Albania (2009–2010), Georgia (2010–2011) and
Kyrgyzstan (2010–2011, age group <15 yrs) the positivity
rates were unexpectedly high (75-100%) while the SARI
positivity rates in Belarus were low. These findings may
suggest a selection or testing bias. Furthermore, the ob-
served differences in influenza positivity rates may be
explained by some countries reporting SARI all year
round and others reporting a selected period in time,
and by the age distribution of SARI patients. In general
most SARI patients were reported in the young age
group (0–15 yrs of age) while the positivity rates were
generally higher in the 15+ age group.
Figure 3 Effect of risk factors on a fatal outcome in influenza-positive SARI patients.
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Differences in health-seeking behaviour may also have
affected the rate of SARI between countries. In a country
with many outpatient visit patients, there may be an
over-capacity of the secondary and tertiary systems
which encourages over-utilisation [21]. Furthermore, the
proportion of positive samples may be affected by the
sensitivity of the test used, the sample type used and
quality of obtaining the specimen, time of sampling after
onset of symptoms and the patient groups sampled. Fur-
thermore, the high proportion of negative samples might
indicate the presence of other respiratory viruses or bac-
teria. It would be useful to test negative samples for
other pathogens as well if the resources for this are
available.
It should be borne mind that data in this study have
been collected as part of national surveillance systems.
The surveillance is usually performed on a voluntary
basis. Therefore limited time may be available and this
could affect the quality and completeness of the data
collection. Also the healthcare systems of the countries
included in this study have different structures and the
lack of electronic recording systems in some countries
may have limited collection of data.
Despite the limitations of this study a total of nine
countries had established SARI surveillance and col-
lected patient data and influenza status, which provides
more insight into the role of influenza in hospitalised
SARI cases. The findings can be used to compare the se-
verity of influenza by season and country, and address
strengths and weaknesses of the current surveillance.
Furthermore, the assessment of possible risk factors
for a severe outcome could be improved by performing
the analysis by influenza type and subtype. Continued
evaluation and review of these recently established SARI
surveillance systems will improve our ability to under-
stand these systems and may allow for better compar-
ability of the surveillance data for SARI cases in the
WHO European Region.
Conclusions
SARI surveillance has been successfully implemented in
countries in the WHO European Region since 2009. This
relatively new system provides a valuable tool for gaining
a better understanding of the contribution of influenza in-
fection to the burden of disease. In this study, a total of
nine countries located in Central and Eastern Europe pro-
vided case-based data on SARI patients. An exploratory
analysis was performed on data from Albania, Georgia
and Romania resulting in identification of risk factors for
ICU admission and death in influenza-positive SARI pa-
tients. The heterogeneous results may implicate differ-
ences in surveillance and healthcare systems.
Public-health surveillance systems need to be evalu-
ated to ensure they are efficient and effective. SARI
surveillance in the European Region is relatively new,
implemented during the pandemic season, so the assess-
ment of these systems will help to identify strengths and
weaknesses in the current data collection and surveil-
lance activities.
Previously, only very limited information was available
on severe influenza in Eastern and Central Europe and
this study fills in a gap. The majority of the countries in-
cluded in this study are low-middle income countries
with a low vaccination uptake and antiviral use. Informa-
tion on risk factors in influenza-positive SARI patients
will help in targeting and prioritising vulnerable popula-
tions for vaccination and antiviral treatment in these
countries. Furthermore, this is a first step towards rou-
tine monitoring of SARI in hospitals in Europe and leads
to a better understanding of the impact of influenza at
the severe spectrum of the disease.
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